Table 3.
Donor | Cell dose | No. mice that engrafted/no. mice total | No. mice with long-term multilineage reconstitution/no. mice total | Frequency of cells that long-term multilineage reconstituted |
---|---|---|---|---|
Old | ||||
TSLK | 5 | 6/9 | 4/9 | 1 in 9.0 |
TSLK | 5 | 3/7 | 2/7 | 1 in 15.4 |
TSLK48– | 5 | 8/9 | 7/9 | 1 in 3.8 |
Reconstituted | ||||
TSLK | 10 | 9/11 | 1/11 | 1 in 105 |
TSLK | 20 | 2/4 | 1/4 | 1 in 70.0 |
TSLK48– | 5 | 6/9 | 2/9 | 1 in 20.4 |
Mobilized | ||||
TSLK | 30 | 8/9 | 3/9 | 1 in 74.5 |
TSLK48– | 5 | 14/18 | 8/18 | 1 in 9.0 |
The indicated number of donor-type (CD45.2+) Thy-1lowSca-1+Lineage–c-kit+ cells from old bone marrow, reconstituted bone marrow, or day-7 cyclophosphanide/G-CSF–mobilized splenocytes were transplanted intravenously into lethally irradiated recipients (CD45.1+) along with 200 000 recipient-type whole bone marrow cells. The frequency of cells that gave long-term multilineage reconstitution (HSCs) was calculated based on limit-dilution (Poisson) statistics.21 Mice were considered long-term multilineage reconstituted if donor-type myeloid, B, and T cells were present for at least 16 weeks after reconstitution.